WO2023213290 - RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47
National phase entry:
Publication Number
WO/2023/213290
Publication Date
09.11.2023
International Application No.
PCT/CN2023/092215
International Filing Date
05.05.2023
Title **
[English]
RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47
[French]
PROTÉINE DE FUSION RECOMBINANTE CIBLANT CD40 ET CD47
Applicants **
BIOSION INC.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Inventors
CHEN, Mingjiu
MA, Mark Zhiqing
WANG, Yujie
XU, Jingjing
Priority Data
PCT/CN2022/091058
06.05.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2199 | |
| EPO | Filing, Examination, Granting | 16654 | |
| Japan | Filing, Examination, Granting | 2569 | |
| South Korea | Filing, Examination, Granting | 2979 | |
| USA | Filing, Examination, Granting | 8140 |
Total:
32,541
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided is a recombinant fusion protein comprising (a) an anti-CD40 antibody or an antigen binding portion thereof comprising a heavy chain variable region and a light chain variable region, and (b) a CD47 binding domain. Provided is a nucleic acid molecule encoding the recombinant fusion protein, a vector comprising said nucleic acid and a host cell transformed or transfected with said vector or with such a nucleic acid. Furthermore, provided is a process for the production of said recombinant fusion protein, a medical use of said recombinant fusion protein and a kit comprising said recombinant fusion protein.[French]
L'invention concerne une protéine de fusion recombinante comprenant (a) un anticorps anti-CD40 ou une partie de liaison à l'antigène de celui-ci comprenant une région variable de chaîne lourde et une région variable de chaîne légère, et (b) un domaine de liaison au CD47. L'invention concerne une molécule d'acide nucléique codant pour la protéine de fusion recombinante, un vecteur comprenant ledit acide nucléique et une cellule hôte transformée ou transfectée avec ledit vecteur ou avec un tel acide nucléique. En outre, l'invention concerne un procédé de production de ladite protéine de fusion recombinante, une utilisation médicale de ladite protéine de fusion recombinante et un kit comprenant ladite protéine de fusion recombinante.